Description of the adverse effect | Number of adverse effects |
Infusion/injection-related response; n (%) | 15 (7.1) |
Bacterial infection; n (%) | 14 (6.7) |
Dermal toxicity; n (%) | 8 (3.8) |
General symptoms; n (%) | 5 (2.4) |
Cardiovascular disorders; n (%) | 5 (2.4) |
Solid tumours; n (%) | 4 (1.9) |
Interstitial lung disease; n (%) | 4 (1.9) |
Others*; n (%) | 4 (1.9) |
Haematological toxicity; n (%) | 3 (1.4) |
Haematological tumour; n (%) | 2 (0.9) |
Tuberculosis; n (%) | 2 (0.9) |
Liver toxicity; n (%) | 2 (0.9) |
Viral infection; n (%) | 2 (0.9) |
Total; n (%) | 70 (33.3) |
The percentage values were calculated by dividing the number of discontinuations per each caused by the total number of discontinuations (210 BT lines).
*Others: anaphylaxis (1), psychiatric disorder (1), lipidic disorder (1) anti-fungal infection (1).